Resmed Inc [RMD] stock is trading at $249.69, down -0.10%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The RMD shares have gain 1.86% over the last week, with a monthly amount glided 3.20%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Resmed Inc [NYSE: RMD] stock has seen the most recent analyst activity on March 19, 2025, when Morgan Stanley initiated its Overweight rating and assigned the stock a price target of $280. On January 16, 2025, Goldman initiated with a Buy rating. Piper Sandler started tracking the stock assigning a Neutral rating and suggested a price target of $252 on January 10, 2025. Stifel initiated its recommendation with a Hold and recommended $250 as its price target on December 13, 2024. Robert W. Baird started tracking with a Outperform rating for this stock on September 24, 2024, and assigned it a price target of $280. In a note dated September 18, 2024, Wolfe Research downgraded an Underperform rating on this stock but restated the target price of $180.
Resmed Inc [RMD] stock has fluctuated between $179.42 and $263.05 over the past year. Currently, Wall Street analysts expect the stock to reach $265 within the next 12 months. Resmed Inc [NYSE: RMD] shares were valued at $249.69 at the most recent close of the market. An investor can expect a potential return of 6.13% based on the average RMD price forecast.
Analyzing the RMD fundamentals
Resmed Inc [NYSE:RMD] reported sales of 5.02B for the trailing twelve months, which represents a growth of 7.92%. Gross Profit Margin for this corporation currently stands at 0.59% with Operating Profit Margin at 0.32%, Pretax Profit Margin comes in at 0.31%, and Net Profit Margin reading is 0.26%. To continue investigating profitability, this company’s Return on Assets is posted at 0.17, Equity is 0.25 and Total Capital is 0.24. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 248.28 points at the first support level, and at 246.88 for the second support level. However, for the 1st resistance point, the stock is sitting at 251.45, and for the 2nd resistance point, it is at 253.22.
Ratios To Look Out For
For context, Resmed Inc’s Current Ratio is 3.41. Further, the Quick Ratio stands at 2.49, while the Cash Ratio is 0.99. Considering the valuation of this stock, the price to sales ratio is 7.29, the price to book ratio is 6.61 and price to earnings (TTM) ratio is 28.03.
Transactions by insiders
Recent insider trading involved FARRELL PETER C, Director, that happened on Jun 04 ’25 when 2000.0 shares were purchased. Chief Financial Officer, Sandercock Brett completed a deal on Jun 02 ’25 to sell 1000.0 shares. Meanwhile, Global General Counsel Rider Michael J sold 41.0 shares on Jun 02 ’25.
